Skip to content
Catalyst

PapersPMID:21942436

Administration of dehydroepiandrosterone (DHEA) enhances visual-spatial performance in postmenopausal women.

Behavioral neuroscience2011The record ↗

findings
2
compound
1
endpoints
2
  1. Finding, limited evidenceno difference foundCortisol concentration
  2. Finding, limited evidenceno difference foundBeck Depression Inventory (BDI) total score
Study, every finding
crossover · 4 weeks
Dose studied, every finding
50 mg oral DHEA daily (capsules compounded by Belmar Pharmaceutical) for one 4-week period
Population, every finding
postmenopausal women aged 55-80 not using hormone replacement therapy, DHEA versus lactose placebo crossover with a 1-week washout

No finding here moved its endpoint.

Study record

Design
crossover trial
Species
human
Population
postmenopausal women aged 55-80 not using hormone replacement therapy
Participants
24
Comparator
placebo
Duration
28 days
Endpoints measured
43